



A background image featuring a handshake in the foreground, with a world map and glowing network lines overlaid on it.

NATIVA JBP

Joint Biosimilar/Biobetter Project

April 2018


A decorative graphic in the bottom right corner consisting of a blue curved shape and a green curved shape.




Nativa Group proposes to develop and transfer **biosimilar/biobetter** products to local partners with giving to them IP rights and establishing business alliance in the region.

Why?

- Biosimilar/Biobetter market still remains attractive for entering by new players.
- Big international generic pharmaceutical companies have already included B/B products in their strategies and pipelines.
- Medium-size local and regional companies may not have enough resources, needed for independent product developing and fast market entry.



Where **JBP** can start?




Regions with fast growing population:

- LatAm region
- Middle East and North Africa regions
- China
- South and South-East Asia

JBP is implemented with support of the Ministry of Economic development of the Russian Federation and Trade Missions in 5 countries (Argentina, Brasil, China, Vietnam, United Arab Emirates)






ONE portfolio

– SEVERAL regional brands


- Portfolio is formed on the basis of overall regional market analysis
- In each region Products will be launched under regional brands



Product	Formulation	Indications	Preclinical	Phase I	Phase III	Current Status Marketed in Russia
Filgrastim	injectable	Chemotherapy-induced Febrile Neutropenia	+	+	+	+
Epoetin beta	injectable	Cancer-related anaemia	+	+	+	+
Interferon α -2b	injectable	Chronic Hepatitis C and B, AIDS-Related Kaposi's Sarcoma, Hairy cell leukemia	+	+	+	+
PEG Interferon α -2b	injectable	Chronic Hepatitis C and B	+	+	+	+

There are already four bio products in the current Portfolio and they are marketed in Russian Pharmaceutical Market


Initial Pipeline* for JBP



Product	Indications	Preclinical	Phase I	Phase III	Forecast Annual Sales WW 2022** US \$ (mln)
Darbepoetin alfa	Anemia Kidney Failure, Oncology	+	+	+	1 928
Infliximab	Crohn"s Disease, ulcer colitis, progressing psoriasis arthritis	+	+	+	4 809
Adalimumab	Rheumatoid Arthritis, Psoriatic Arthritis, Adult Crohn"s Disease	+	+		22 006
Interferon beta-1a	Multiple Sclerosis	+	+		2 748
Trastuzumab	Adjuvant or Metastatic Breast Cancer, Metastatic Gastric Cancer	+			1 542
Bevacizumab	Glioblastoma, Metastatic colorectal cancer	+			4 616
Eculizumab	Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome	+			4 900
Epoetin alpha	Chronic Kidney Disease-Associated Anemia	+			1 940

* **Biobetters: under development**

** Source: Evaluate Pharma




Nativa Group

- Initiation and project planning
- API and FDF development
- Coordination of clinical trials
- FDF technology transfer on regional manufacturing sites
- API supply to regional partners
- Coordination of marketing strategies
- Product development, modification and DMF actualization (if needed)


Regional partners

- FDF manufacturing (own site or CMO)
- Conducting clinical trials and market authorization
- Market Access
- Sales and Marketing
- Pharmacovigilance activities




- They are interested in **entering** bioproducts markets **and**
- They are ready for international **collaboration on research and development** **and**
- They could **transfer** selected bioproducts on their own production site or CMO **or**
- They could be interested in **creating a new biopharmaceutical plant** through partnership with investment fund and Nativa Group.





- **Vladimir A. Mefodovsky**, Chief Development Officer
- **Olga Ashikhmina**, Head of Product Portfolio Development Department
- **Alexander Li**, Head of Business development group





Thanks

Contact details:

li@nativa.pro

ashihmina@nativa.pro

